Advanced Cell Technology Expands Senior Scientific Team into California.WORCESTER, Mass. -- Michael West, Ph.D., President and Chief Scientific Officer of A.C.T. Holdings, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :ACTH ACTH: see adrenocorticotropic hormone. ACTH in full adrenocorticotropic hormone Polypeptide hormone made in the pituitary gland. ) and its wholly-owned subsidiary, Advanced Cell Technology, Inc. (collectively, "ACT") announced today the expansion of ACT's senior scientific team with the addition of senior scientists that will add to the existing California team. California research is an increasing focus for ACT, given voters recently approved $3 billion in state funds for stem cell research. David Larocca, Ph.D., Associate Director Previously Associate Director of Research at Selective Genetics, Inc., Dr. Larocca brings more than 20 years experience in biotechnology and discovery research to Advanced Cell Technology. In his former position, Dr. Larocca invented novel gene therapy methods using bacterial viruses and novel technology for discovering drug targeting agents and their receptors. He holds over a dozen patents in the fields of functional genomics, gene delivery and cancer immunotherapy. He received a Ph.D. from the University of Southern California The U.S. News & World Report ranked USC 27th among all universities in the United States in its 2008 ranking of "America's Best Colleges", also designating it as one of the "most selective universities" for admitting 8,634 of the almost 34,000 who applied for freshman admission in Cell and Molecular Biology Cell and Molecular Biology may refer to:
James T. Murai, Ph.D., Associate Director With more than 38 published scientific papers and formerly Senior Scientist at Immunetech, Inc., Dr. Murai has extensive background and experience in biochemistry and reproductive endocrinology and a successful track record in assay development and problem solving in a variety of research areas including immunology/allergy, reproductive endocrinology, and endocrine diseases. He served as Research Endocrinologist at the University of California, San Francisco for over 10 years. Dr. Murai received a Ph.D. in Biochemistry from the University of California The University of California has a combined student body of more than 191,000 students, over 1,340,000 living alumni, and a combined systemwide and campus endowment of just over $7.3 billion (8th largest in the United States). at Los Angeles. R. Geoffrey Sargent, Ph.D. As a full-time consultant, Dr. Sargent brings to the team more than 15 years scientific experience in the Molecular, Biology, Cellular Biology, Biochemistry and Genetics of DNA repair, DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. Recombination recombination, process of "shuffling" of genes by which new combinations can be generated. In recombination through sexual reproduction, the offspring's complete set of genes differs from that of either parent, being rather a combination of genes from both parents. , and Deoxyribonucleotide deoxyribonucleotide /de·oxy·ri·bo·nu·cleo·tide/ (-noo´kle-o-tid) a nucleotide having a purine or pyrimidine base bonded to deoxyribose, which in turn is bonded to a phosphate group. Metabolism in Mammalian cells and bacteria to Advanced Cell Technology. Dr. Sargent was formerly the Director of Research at DNAtriX, Inc. He received a Ph.D. in Biochemistry from Oregon State University Oregon State University, at Corvallis; land-grant and state supported; coeducational; chartered 1858 as Corvallis College, opened 1865. In 1868 it was designated Oregon's land-grant agricultural college and was taken over completely by the state in 1885. . "We are excited to announce our scientific expansion in California, as we look to take advantage of the positive climate for embryonic stem cell Embryonic stem cells (ES cells) are stem cells derived from the inner cell mass of an early stage embryo known as a blastocyst. Human embryos reach the blastocyst stage 4-5 days post fertilization, at which time they consist of 50-150 cells. ES cells are pluripotent. research due, in part, to the recent passage of Proposition 71. We see a long term potential to expand scientific development, and commercialize our current and future technologies," said Dr. West, who currently resides in the San Francisco Bay Area “Bay Area” redirects here. For other uses, see Bay Area (disambiguation). The San Francisco Bay Area, colloquially known as the Bay Area or The Bay . "With the expansion of our scientific team, based both here in California and in Massachusetts, ACT is well positioned to continue expanding its commercialization of technologies focused on the emerging field of regenerative medicine," said William Caldwell, Chief Executive Officer of ACT. About Advanced Cell Technology A.C.T. Holdings, Inc., a Nevada corporation, and its wholly-owned subsidiary, Advanced Cell Technology, Inc., a Delaware corporation, is a leading biotechnology company applying stem cell technology in the emerging field of regenerative medicine. The company is currently headquartered in Worcester, Massachusetts. For more information about Advanced Cell Technology visit http://www.advancedcell.com Forward-Looking Statements Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for A.C.T. Holdings, Inc. and its subsidiary, Advanced Cell Technology, Inc., and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended March 31, 2005. Forward-looking statements are based on the beliefs, opinions, and expectations of the Company's management at the time they are made, and the Company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion